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Abstract
Parathyroid carcinoma is a rare endocrine malignancy. The reported incidence is from 0.5 to 5% of primary hyperparathyroidism cases in various series. The
cause is unknown, but clinical correlations with different genetic syndromes exist. Mutations in the HPRT2 gene seem to play a signiﬁcant role in the path-
ogenesis of this disease. Men and women are equally affected, usually in the fourth or ﬁfth decade of life. Most patients will present with signs and symptoms of
hypercalcaemia. Cases of non-functioning carcinoma are exceedingly rare. Surgical resection is the most effective method of treatment and palliation.
A signiﬁcant proportion of patients will experience recurrence, and will need further surgical and, eventually, medical management of hypercalcaemia. The
disease is progressive but slow growing. Most patients will require multiple operations to resect recurrent disease. The main cause of morbidity and mortality is
the sequela of uncontrolled chronic hypercalcaemia rather than tumour burden. The current paper will review the epidemiology, pathogenesis, clinical
presentation and diagnostic work-up of this disease. Surgical management in different scenarios is reviewed in detail, followed by other types of treatment and
management of incurable disease.
 2010 The Royal College of Radiologists. Published by Elsevier Ltd.
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Sources of Information
A search was made on Medline, using PubMed clinical
queries, of English-language literature using parathyroid
carcinoma, parathyroid cancer, parathyroid malignancy and
human in the following categories: epidemiology, cause,
diagnosis and management. The full text of relevant papers
wasobtainedand reviewed.Additional speciﬁc searcheswere
made as necessary. Both original papers and reviews were
examined, and those with the most reliable methodologies
and highest citation rates were selected.Introduction
Parathyroid carcinoma is a rare disease. Fewer than 1000
cases have been reported in the entire English-language
literature [1]. Patients usually present with severeAuthor for correspondence: J.P. Shah, Head and Neck Service, Depart-
ment of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave,
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doi:10.1016/j.clon.2010.04.007symptoms of hypercalcaemia, as if they are afﬂicted with
‘hyperparathyroidism on steroids’. Although clinically
similar to adenoma, parathyroid carcinoma has its own
unique features. Parathyroid adenomas are much more
common in women, but carcinoma occurs with equal
frequency in men and women [2e4]. On average, patients
with carcinoma are 1 decade younger than patients with
adenoma [2,5]. Both benign andmalignant parathyroid cells
are fairly resilient and can take hold in almost any tissue. In
spite of this survival advantage, the disease commonly has
an indolent and slow course, and most patients succumb to
complications of relentless hypercalcaemia rather than
tumour invasion and spread. None of these, however, are
strict rules. Indeed, the very ﬁrst documented case of
parathyroid cancer was a non-functioning carcinoma
reported by The Swiss surgeon, Fritz De Quervain, in 1904
[6]. His patient was a 68-year-old man who presented with
a large neck mass and soon died of local recurrence and
pulmonary metastases. De Quervain did not mention any
signs or symptoms of hypercalcaemia. Uncommon presen-
tations and courses continue to be reported in published
studies. However, even in common scenarios, it is not
always easy to differentiate between parathyroid carcinoma
and adenoma. These features can mislead the managingOpen access under CC BY-NC-ND license.
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egies and approaches. A less-than-optimal approach will
deprive patients from receiving the best chance of cure,
which to this date remains complete surgical excision
[3e5,7]. Although no breakthroughs have been made in
curative options, understanding of molecular pathogenesis
of parathyroid carcinoma has expanded in recent years.
New markers are helpful in making the diagnosis more
certain in ambiguous cases. In addition, more medications
have become available in management of incurable
scenarios. The present brief overview will focus on the
current principles of management of parathyroid cancer.Epidemiology
By all accounts, parathyroid cancer is a rare entity [2,3].
The incidence and prevalence of disease are usually repor-
ted as the percentage of patients presenting with primary
hyperparathyroidism, because prevalence in the general
population is extremely low. The largest series comes from
the USA, based on the National Cancer Data Base. Over the
years, many different reports have estimated the incidence
of parathyroid cancer as <1% in patients diagnosed with
primary hyperparathyroidism [8e12]. Exceptions are
reports from Japan, which report an incidence of about 5%
[13,14]. Parathyroid carcinoma occurs equally in men and
women, and the average patient is in the fourth or ﬁfth
decade of life, although patients as young as 8 years of age
have been reported [15].Pathogenesis and Molecular Biology
The cause of parathyroid cancer is unknown. However,
a few revealing associations exist between cancer devel-
opment and a number of clinical scenarios and genetic
mutations. Prior neck radiation and end-stage renal disease
have been associated with increased incidence of para-
thyroid cancer [16e19]. The correlation of radiation,
however, is quite weak [3] and not as prominent as in the
development of benign adenomas. Parathyroid cancer has
also been reported in cases of MEN 1 [20e22] and MEN 2A
[23], but not in any cases of MEN 2B. Increased risk is also
observed in the rare autosomal-dominant disorder, familial
hyperparathyroidism [24e27]. The most common chro-
mosomal imbalances are losses of 1p and 13q. Gains are
seen in 19p, Xc-q13, 9p33qter, 1q and 16p [28]. In contrast
to adenoma, loss of 11q13 is not seen in carcinoma [28].
Several different mutations have been implicated in the
pathogenesis of parathyroid cancer. These include the reti-
noblastoma (Rb) [29,30], p53 [31], breast carcinoma
susceptibility (BRCA2) [32,33] and cyclin Dl/parathyroid
adenomatosis gene 1 (PRAD1) genes [34,35]. None of these
have been assigned a primary role in pathogenesis. The
most extensive evidence comes from study of a rare genetic
syndrome called ‘hereditary hyperparathyroidismejaw
tumour syndrome’ [36e38]. In this syndrome, patients
develop primary hyperparathyroidism and mandibular andmaxillary ﬁbro-osseous lesions. In addition, up to 15% of
patients can develop parathyroid cancer. The responsible
gene is known as HRPT2 and codes for a nuclear protein
named ‘paraﬁbromin’ [22,38e49]. This mutation is found
much more commonly in cases of sporadic parathyroid
cancer than in benign adenomas (up to 76% of carcinomas
vs 0.8e1.8% of adenomas) [41,50,51]. This evidence points to
an important role for this mutation in the pathogenesis of
parathyroid carcinoma. Paraﬁbromin is mainly a nuclear
protein [52e58] and acts as a regulator of transcription.
Overexpression of this protein causes inhibition of cell
proliferation and G1 phase arrest [59e61]. Non-functional
isoforms, such as mutations in hereditary hyperparat-
hyroidismejaw tumour syndrome, have anti-apoptotic
effects. More studies are underway to elucidate further
mechanisms of tumourigenesis and growth modulation
related to this protein.Pathology
The diagnosis of parathyroid carcinoma can be chal-
lenging. These tumours are usually solitary and arise from
a single gland; however, there have been reports of multi-
glandular involvement [62]. Both right and left inferior
glands have been counted as the most common location
[3,8,63]. Ectopic tumours usually arise from glands in the
mediastinum, but ectopic location does not increase the
chance of malignant transformation of a gland. Cases of
synchronous parathyroid carcinoma and adenoma have
been reported [20]. Grossly, tumours are usually quite large
with an average diameter of >3 cm and can weigh between
2 and 10 g. They are often irregular, ﬁrm to hard, and have
a greyish-to-white colour [25]. Carcinomas are tenaciously
adherent to adjacent tissues [64]. Tumour cells can inﬁltrate
the ipsilateral lobe of the thyroid, the strapmuscles and even
the recurrent laryngeal nerve, trachea or oesophagus [3].
Microscopically, the tumour is surrounded by a capsule,
and ﬁbrous septa extend into the tumour creating a lobular
appearance. Tumour cells are large and mainly consist of
chief cells, with sparse oxyphil and transitional oxyphil cells
between the chief cells [65]. Tumour cells are arranged in
trabecular, solid or acinar structural patterns [66]. Mitotic
ﬁgures are usually present. Focal calciﬁcation, cystic
changes and coagulative necrosis can be seen, and capsular
invasion is commonly seen. Vascular invasion is also seen
but is less common than capsular invasion [10].Clinical Presentation
The overwhelming majority of parathyroid cancers are
functioning tumours. Therefore, patients most often
present with symptoms and signs of hypercalcaemia
[4,25,67e69]. Manifestations of hyperparathyroidism
appear well before local invasion of tumour produces any
symptoms. Symptoms of hypercalcaemia, such as fatigue,
malaise, weakness, weight loss and anorexia, are common.
Many organs are affected by elevated calcium levels.
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symptoms (e.g. nausea, vomiting, abdominal pain, peptic
ulcer, pancreatitis and constipation) are all described. More
prominent are symptoms of renal and skeletal involve-
ment. Patients quite often complain of polyuria, renal colic
and nephrolithiasis. Bone pain and pathological fractures
are also reported. Most patients manifest evidence of both
renal and skeletal involvement at the time of presentation,
contrary to benign adenomas. On physical examination, up
to 70% of patients present with a palpable neck mass; this is
quite rare in benign disease [67].
Similar to benign primary hyperparathyroidism, levels of
calcium and parathyroid hormone (PTH) are elevated and
usually to an exaggerated degree. In a subset of patients
with carcinoma, a different moiety of PTH is produced. The
signiﬁcance of this form is not yet clear [70]. Serum levels of
alkaline phosphatase and a and b subunits of human cho-
rionic gonadotrophin are also raised [71]. On imaging
studies, evidence of bony involvement (e.g. salt and pepper
skull, osteitis ﬁbrosa cystica, subperiosteal bone resorption)
can be seen [67].
Non-functioning carcinomas are exceedingly rare
(19 cases since 1929), and usually present with signs and
symptoms of local growth and invasion (e.g. neck mass,
hoarseness, dysphagia) [72].Differential Diagnosis
The primary goal is to differentiate between malignant
and benign disease before any surgical attempts. This task
can be quite difﬁcult as there are no speciﬁc differentiating
characteristics for parathyroid cancer. Usually, the effects of
hypercalcaemia are more pronounced in carcinoma than
adenoma, and a few effects occur much more frequently in
patients with carcinoma. These characteristics are sum-
marised in Table 1. In general, severe hypercalcaemia,
younger age, male gender, hypercalcaemic crisis, concur-
rent bone and renal involvement, and palpable mass should
raise the suspicion of malignant disease [25,67,73]. In cases
of palpable disease or obvious mass, ﬁne needle aspirationTable 1
Frequency of clinical features in benign vs malignant parathyroid
tumours
Benign
disease
Malignant
disease
Women:men ratio 3e4:1 1:1
Average age at presentation
(years)
55 48
Renal involvement <20% 56e84%
Serum calcium 11.2 mg/dl >14 mg/dl
Serum parathyroid hormone Mild
elevation
3e10-fold
elevation
(up to 75-fold)
Palpable mass Rare 50e70%
Radiological skeletal features
(osteitis ﬁbrosa cystica etc.)
<5% 44e91%
Hypercalcaemic crisis Very rare More commonis not usually recommended. This is due to the extreme
difﬁculty of differentiating between benign and malignant
disease on cytology [74,75], in addition to the potential for
seeding of tumour cells in the tract [76]. Differentiating
between malignant and benign lesions based on tissue
specimens can be quite difﬁcult. The only unequivocal proof
of malignancy is the presence of metastases. However, this
feature is not commonly seen at presentation [77]. Many
pathological criteria have been proposed to distinguish
between benign and malignant lesions. Early criteria, such
as those proposed by Schantz and Castleman in the 1970s
[78], are valuable but not absolute. They describe using
a combination of mitotic ﬁgures, ﬁbrous trabeculae, and
capsular and vascular invasion to determine malignancy.
However, later investigators showed that none of these
criteria are sufﬁciently sensitive or speciﬁc to conﬁrm or
discard the diagnosis reliably. Mitotic activity and trabec-
ular patterns can be seen in benign lesions, as reported by
McKeown et al. [79], Bondeson et al. [65] and others
[80e82]. On the other hand, capsular invasion can only be
seen in a portion of specimens, and vascular invasion in
even fewer cases [83,84]. These difﬁculties, naturally, have
intensiﬁed interest in developing other methods such as
immunohistochemistry and DNA analysis [85]. No single
marker thus far has shown to be perfectly sensitive and
speciﬁc [67]. Staining for paraﬁbromin [86], Rb expression
[29,30,32], Ki-67 [87] and galectin-3 [88] have all been
used. Most recent studies suggest using a combination of
different markers. A recent report by Frenandez-Ranvier
et al. [89] proposed using a combination of loss of paraﬁ-
bromin plus Rb expression and overexpression of galectin-3
as a reliable differentiating proﬁle of parathyroid carcinoma
from atypical adenoma and other non-malignant lesions.
Pathological diagnosis of parathyroid carcinoma
continues to be a challenge. In the absence of a gold
standard test, a multidisciplinary approach, considering all
clinical, biochemical and structural aspects of the disease,
offers the best chance for accurate diagnosis.Work-up
Levels of PTH and calcium are measured routinely in all
patients. Neck ultrasound and 99mTc-sestamibi scan are the
most common imaging studies in benign disease [90]. These
arealso of value inmalignant cases [75].Ultrasoundprovides
general information about the location of the lesion and its
structure [91]. Sestamibi scan can reveal abnormal and
ectopic parathyroid tissue in theneck and elsewhere [92,93].
In cases where malignancy is suspected, higher-resolution
anatomical studies are of considerable value [94]. Computed
tomography (CT) with contrastwill provide excellent details
on the location of the lesion and its relation with other
structures [95], and can also reveal invasion of surrounding
structures and enlarged lymph nodes. Magnetic resonance
imaging (MRI)with gadoliniumand fat suppressionwill give
the best detail on soft tissues of the neck, and can supple-
ment further information, speciﬁcally in the setting of pre-
operative assessment. MRI is also superior to CT in assessing
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signiﬁcant artefacts in CT studies [96]. Fluorodeoxyglucose-
positron emission tomography (FDG-PET) has mainly been
used in adenoma cases, and very few reports exist on its use
inparathyroid carcinoma [97]. A practical point to remember
is that the lytic bone lesions (Brown tumours) appear FDG
avid on PET. In cases of parathyroid carcinoma, they can be
mistaken as bonemetastases [97]. Interest in fusion of Single
Photon Emission Computed Tomography (SPECT) and CThas
increased recently. SPECT/CT has been used in localising
parathyroid adenomas [98], but the results are not consis-
tent. SPECT/CT is more sensitive than sestamibi and as
speciﬁc. However, in localisation of multifocal disease,
SPECT/CT is not superior to sestamibi. Use of SPECT/CT has
not been reported in parathyroid carcinoma to date. Lastly,
selective venous catheterisation and PTH measurement can
beused if non-invasive tests have failed to reveal the location
of the lesion or when results are ambiguous [91].Management
The management of parathyroid cancer can be divided
into two categories: attempts aimed at potential cure, and
therapeutic interventions to control incurable cases.
Complete en-bloc surgical excision is the only technique
that can potentially offer cure [67]. Neither radiation norSuspicion o
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Fig. 1. Approach to management of parathyrochemotherapy has shown evidence of tumour eradication
[3]. Surgical excision and removal of hormone-producing
tissue does offer meaningful alleviation of symptoms and is
indicated. In cases of widespread metastatic disease or
surgically unresectable disease, different types of medica-
tion have been tried to reduce serum calcium levels and
alleviate the effects of rampant hypercalcaemia. The general
approach to management of parathyroid carcinoma is
described in Fig. 1.
Surgical Management
Surgical excision can be carried out in two clinical
scenarios: initial surgery at the time of diagnosis of hyper-
parathyroidism, and surgical excision of recurrent or
metastatic disease.
Complete en-bloc resection of the tumour offers the best
chance for cure. In order to achieve this, the surgeon should
approach the operation with adequate preparation. This
starts well before the operative procedure itself. In cases of
suspected carcinoma, it is prudent to proceed with
adequate anatomical imaging, including CT and MRI in
addition to ultrasound and sestamibi scan that are usually
obtained in benign cases. Attention should be paid to
detailed examination and interpretation of these studies to
gather as much information as possible before embarking
on tumour excision. Knowledge of the status of vocal cordf 
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laryngeal nerve involvement, as this can signiﬁcantly
change the operative plan and extent. During surgery, it is
imperative to adhere to the principles of head and neck
surgery, and oncological resection. These include adequate
exposure, maintaining a bloodless ﬁeld and attention to
surrounding structures [99]. As it is possible to encounter
both adenoma and carcinoma synchronously, all four
glands should be found and examined [20]. The need for
thorough exploration rules out minimally invasive
approaches that have limited exposure. After adequate
exploration, the lesion should be removed with minimal
manipulation in an en-bloc fashion. This requires, at
minimum, removal of the ipsilateral lobe of the thyroid
[100e102]. If there is any evidence of invasion of the strap
muscles or other structures, the tissues should be removed
in continuity with the tumour. Every effort should be made
not to rupture the capsule of the tumour and spill tumour
cells in the ﬁeld. If there is evidence of nodal involvement,
regional lymph node dissection of that compartment
should be undertaken. In most cases, the recurrent laryn-
geal nerve can be preserved without jeopardising its
integrity. However, if the nerve is involved, it should be
sacriﬁced [91]. More extensive operations have been
advocated by a few investigators. Holmes et al. [69]
recommend isthmusectomy, skeletonisation of the
trachea, removal of the ipsilateral strap muscles and
resection of the recurrent laryngeal nerve in addition to
removal of the tumour and the ipsilateral lobe of the
thyroid. This approach has not gained popularity and is not
usually undertaken. Therapeutic neck dissection is recom-
mended if there is evidence of disease [100]. Prophylactic
lateral neck dissection, on the other hand, has been tried
previously and did not improve survival but increased
morbidity [12]. Therefore, prophylactic neck dissection is
not currently recommended. Use of a rapid PTH test has
been reported in parathyroid cancer. If this tool is available,
its use can be helpful. If the PTH level falls signiﬁcantly and
speciﬁcally within normal limits, the surgeon has high
assurance that most of the disease, if not all, has been
removed. If the values remain elevated, the decision-
making can be complicated. This can be due to residual
tumour tissue in the neck or undetected metastatic foci. At
that time, the surgeon should make a decision whether or
not to pursue further exploration, considering that
unguided exploration may not improve outcome but will
probably increase morbidity. After surgery, close moni-
toring of calcium levels and adequate replacement is
necessary to avoid severe hypocalcaemia due to ‘hungry
bone syndrome’.
If the diagnosis of parathyroid cancer is made after initial
excision, decision-making is more complicated. If the
patient is normocalcaemic, PTH levels are within normal
limits and the diagnosis is solely based on suspicious
pathology without evidence of extensive vascular or
capsular invasion, most tend to follow the patient closely
without an attempt at immediate re-excision [103]. Patients
need to be followed closely with serial PTH measurements
and cervical ultrasound. If the patient continues to besymptomatic, PTH levels remain elevated or there is
extensive evidence of vascular and capsular invasion, re-
operation may be beneﬁcial [67]. In these cases, adequate
pre-operative imaging is of importance to localise the
disease as accurately as possible. This will guide the surgeon
in the conduct of the operation and can potentially improve
the success rate and reduce complications.
The importance of en-bloc resection on the future course
of the disease has been well described. Patients who were
diagnosed before or during surgery, and therefore had an
en-bloc resection, had a recurrence rate of 33%. On the other
hand, patients who were diagnosed after initial surgery had
a local recurrence rate of more than 50% [3,12,100].
All patients need to be followed closely after surgery.
In the immediate postoperative period, close monitoring
of serum calcium levels and adequate replacement is
mandatory. Intravenous calcium in addition to oral
supplementation and calcitriol is usually necessary. The
goal is to keep calcium levels at the lower limit of normal
[67]. After bone replenishment and recovery of the
remaining gland, most patients can be maintained on
a normal diet with minimum oral supplementation of
calcium. Calcium levels and PTH have to bemonitored every
3 months after this initial period to detect recurrence.
Surgical management of recurrent disease
In spite of all technological and technical advances,
recurrence is very common in parathyroid carcinoma [100].
Different case series report recurrence rates as high as 100%
[104] and as low as 40%. Most series put the recurrence rate
above 50%. As mentioned before, patients who had
a complete resection at the time of initial surgery have
a lower recurrence rate. Unfortunately, a signiﬁcant
proportion of patients are not diagnosed at initial surgery
and do not undergo complete resection [105]. On average,
recurrence occurs 2e3 years after initial surgery [100].
Much longer time lapses, up to 23 years, have been reported
previously [67]. Patients present with gradually increasing
PTH and serum calcium levels. Severe hypercalcaemic crisis
is rare. The treatment strategy consists of controlling
hypercalcaemia, localising studies and surgical excision of
resectable disease.
Parathyroid carcinoma metastasises through both
lymphatic and haematogenous routes. The most common
sites of dissemination are the regional lymph nodes fol-
lowed by the lungs, bones and liver in descending order.
After medical control of hypercalcaemia, adequate imaging
studies should be obtained to localise and assess the extent
of disease. Ultrasound is helpful in studying the lymphatics
of the neck. Sestamibi scan will show local and metastatic
disease. If further operations are planned, anatomical
studies such as CT and MRI are indicated. In cases where
non-invasive studies are inconclusive, selective venous
catheterisation and PTH measurement may be necessary.
Resectable disease should be managed surgically.
Removal of all functioning tumour tissue gives the most
effective relief of symptoms [67,91,106]. Regional disease in
the neck or mediastinum should be resected with margins
as wide as possible. Distant metastatic foci that are
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may require multiple operations and this approach, in fact,
is justiﬁed as it offers the best palliative option [67,91,106].
Most patients will require two to three operations in the
course of disease. The reported morbidity of operations can
be as low as 6.2% if one excludes intentional sacriﬁce of the
recurrent laryngeal nerve [91]. The frequency of intentional
sacriﬁce of the recurrent laryngeal nerve is higher in repeat
operations than in initial operations. Metastatectomy [107]
is carried out routinely if the disease is limited and tech-
nically resectable. Mediastinal lymphadenectomy, and open
or thoracoscopic lung resections are the most common
procedures in the chest.
Most patients will beneﬁt from excision of recurrent
disease and a reduction in the levels of PTH and serum
calcium after surgery, and most patients will have symptom
relief. Pre-operative calcium level is a good predictor of
operative success. Patients with levels of 13.5 2.0 mg/dl
had a signiﬁcantly higher rate of normalisation in compar-
ison with patients whose levels were 16.31.9 mg/dl
before surgery, according to Kebebew et al. [91]. Unfortu-
nately, surgical resection, as effective as it is in controlling
recurrent disease, rarely results in cure. Most patients will
have further recurrences.
Radiotherapy
Traditionally, radiotherapy was not deemed effective in
the treatment of parathyroid carcinoma, either as a single
technique or in addition to surgery [3]. In the past decade,
reports from three different institutions have challenged
this notion. Chow et al. [108] from Princess Margaret
Hospital in Toronto, Munson et al. [109] from the Mayo
Clinic, and Busaidy et al. [83] from MD Anderson Cancer
Center reported lower recurrence and longer disease-free
survival with use of adjuvant radiotherapy. All three series
were very small. The total number of patients treated with
adjuvant radiotherapywas 16. Of these 16 patients, only one
developed recurrence, which was much lower than in the
non-treated group. These limited data are provocative but
should be examined carefully. Thus, there may be a role for
adjuvant radiotherapy in control of the disease. Currently,
the best practice seems to be approaching each patient
individually in a multidisciplinary fashion. Due to very low
incidence of this disease, the feasibility of a randomised
study seems remote.
Chemotherapy
Most data on the use of chemotherapy in parathyroid
cancer come from case reports [25,110,111]. No structured
trials have ever been carried out. Considering the rarity of
this disease, this is not surprising. Reports of response in
both non-functioning and functioning carcinomas do exist
[110, 112]. However, these remain limited to single case
reports. Wynne et al. [25] reported the use of mithramycin,
5-ﬂuorouracil and doxorubin alone or in combination in ﬁve
patients, and a combination of cyclophosphamide, vincris-
tine and dacarbazine in another patient. The ﬁrst ﬁvepatients did not see any beneﬁt from chemotherapy, and
the course of disease in the sixth patient was not reported at
the time of publication. In general, chemotherapy has not
been promising in parathyroid cancer. The advent of new
agents and better understanding of the pathogenesis of this
disease may change this in future. However, rare occurrence
will always be an obstacle to carrying out large-scale
studies.
Medical Management of Hypercalcaemia
Parathyroid carcinoma becomes a chronic disease for
most patients. As mentioned previously, most of the
morbidity and mortality from this disease come from
uncontrolled hypercalcaemia. Medical management of
hypercalcaemia becomes necessary in patients with wide-
spread metastatic or unresectable local disease. Medical
management is also indicated in hypercalcaemic crisis and
for patients awaiting surgical intervention.
Urgent management of hypercalcaemia requires volume
expansion with saline infusion and use of loop diuretics to
promote renal excretion of calcium [113]. Eventually, pres-
ervation of bone mass becomes necessary. Bisphophonates,
such as clodronate, etidronate, pamidronate and zoledro-
nate, act through interference with osteoclasts. Potent
agents such as pamidronate and zoledronate can be used
intravenously [67]. These agents can control hyper-
calcaemia for a while, but unfortunately most patients will
become resistant eventually. Use of other agents is more
limited due to their toxicity. Mithramycin is toxic and not
very effective, but can be used in life-threatening scenarios
unresponsive to bisphosphonates [67]. Plicamycin and
gallium nitrate [114] can be used, but the former is only
effective transiently and is toxic, and the latter is
nephrotoxic.
Calcitonin does reduce serum calcium levels but again
only transiently. The long-acting somatostatin analogue,
octreotide, has been used in two patients with good results
in lowering the PTH level [115,116]. Immunotherapy
directed against PTH [117,118] and dendritic cells [119] has
also been reported.
Calcimimetics are allosteric modulators of parathyroid
calcium-sensing receptor. Calcimimetic agents bind to these
receptors and increase their sensitivity to extracellular
calcium. This action results in a reduction of PTH secretion
by parathyroid cells [120]. R-568, a ﬁrst-generation calci-
mimetic, controlled calcium levels effectively in one patient
with metastatic parathyroid cancer for 2 years. Cinacalcet,
a second-generation calcimimetic, was used in a multi-
centre study of inoperable metastatic parathyroid carci-
noma [121]. In this study, 29 patients were treated with
cinacalcet. Two-thirds of patients (18/29) responded to the
treatment with an average reduction in serum calcium level
from 15 mg/dl to 11.2 mg/dl. Patients with the highest
calcium levels at study entry had the most pronounced
response. The dose of cinacalcet titrated from 30 mg Bd up
to 90 QID. The mean duration of treatment was 328 306
days. Most patients tolerated the drug quite well, with
nausea and vomiting being the most common side-effect.
B. Givi, J.P. Shah / Clinical Oncology 22 (2010) 498e507504Interestingly, in spite of a reduction in serum calcium levels,
PTH levels did not decrease signiﬁcantly. Currently, there is
no clear explanation for this observation. There is no
evidence that cinacalcet will alter the course of parathyroid
cancer. Therefore, it cannot replace surgical excision in
cases of resectable disease. However, in patients with
widely metastatic disease, this agent can potentially alle-
viate the effects of hypercalcaemia. This agent can also be
used safely in patients with renal insufﬁciency, which is
common in patients with longstanding parathyroid cancer.Prognosis
Parathyroid carcinoma usually has a slow but progressive
course. The tumour invades surrounding structures and
spreads to regional lymph nodes. Tumour cells also
disseminate haematogenously, and distant metastases
occur in lungs, liver and bones. The most important factor
affecting prognosis is the completeness of tumour resec-
tion. Patients who undergo complete en-bloc tumour
resection can have survival rates as high as 90% at 5 years
and 67% at 10 years [122]. Negative prognostic factors
include lymph node metastases at the time of diagnosis,
distant metastases and non-functioning carcinomas [3]. In
spite of best efforts, a signiﬁcant proportion of patients
develop recurrence. Recurrence rates from 33 to 78% have
been reported in published studies. Most recurrences will
manifest in the ﬁrst 3 years, but recurrences as late as 20
years have been reported [67,123]. Once the disease has
recurred, the chances of cure are remote. However,
aggressive resection of residual disease and meta-
stasectomy does improve survival.
The largest series of patients with parathyroid carcinoma
based on the Surveillance, Epidemiology and End Results
(SEER) database [2] put 5-year survival at 86% and 10-year
survival at 49% for all patients. Other series reported 5-year
survival from 40 to 90% [122]. The most common causes of
death are complications of hypercalcaemia (renal failure,
cardiac arrhythmias, pancreatitis) rather than tumour
burden [25,75,103,106].Summary
Parathyroid carcinoma is a rare disease. Men and women
are equally affected, usually in the fourth or ﬁfth decade of
life. The most common presentation is complications of
hypercalcaemia. The cause is not known, but mutations in
the HRPT2 gene seem to play a crucial role in pathogenesis.
Differentiation between benign and malignant disease is
difﬁcult on tissue specimens. The best chance of cure is
complete surgical resection at the time of ﬁrst operation.
Recurrence is common and many patients require multiple
resections to reduce the tumour burden. Other treatments
such as chemotherapy and radiation have not been reported
to be effective, although the data are not comprehensive.
In cases of unresectable disease, medical management
with diuretics, bisphosphonates and, more recently,calcimimetics is helpful in alleviating symptoms. Other
experimental treatments, such as immunotherapy or newer
chemotherapy agents, have been reported with sporadic
success. More research is needed to elucidate the genetic
causes of parathyroid carcinoma. Designing clinical trials for
new treatments is quite difﬁcult considering the rarity of
this disease. The best chance for success relies on multi-
institutional, multidisciplinary designs to accrue an
adequate number of patients. Short of a major biological or
molecular breakthrough, surgery remains the most effec-
tive therapeutic and palliative option.Conﬂict of Interest
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